
Press Release|Articles|November 12, 2024
Camber Pharmaceuticals Launches Generic Xeloda®
Key Takeaways
- Capecitabine Tablets, USP, are now part of Camber Pharmaceuticals' product offerings, targeting multiple cancer types.
- Indications include colorectal, breast, gastric, esophageal, gastroesophageal junction, and pancreatic cancers.
Advertisement
Camber Pharmaceuticals is excited to announce the addition of Capecitabine Tablets, USP, to our product portfolio. Capecitabine is a nucleoside metabolic inhibitor indicated for the treatment of several cancers, including:
- Colorectal Cancer
- Breast Cancer
- Gastric, Esophageal, or Gastroesophageal Junction Cancer
- Pancreatic Cancer
For more information about these indications, please visit our website:
- 150 mg – 60 count bottles
- 500 mg – 60 count and 120 count bottles
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
2
Olezarsen Receives FDA Approval to Reduce Triglycerides, Risk of Acute Pancreatitis in Severe Hypertriglyceridemia
3
ADA 2026: Diabetes Technology Innovations Expand Beyond Traditional CGM Use
4
FDA Grants Fast Track Designation to VS-7375 for KRAS G12D-Mutated Advanced NSCLC
5





















































































































